Loading...
•
Jun 30, 2022
Pacific Biosciences Q2 2022 Earnings Report
Pacific Biosciences reported increased revenue driven by instrument and consumable revenue, but experienced a net loss due to increased operating expenses.
Key Takeaways
Pacific Biosciences reported Q2 2022 financial results, highlighting revenue growth driven by strong instrument and consumable sales. However, the company experienced a net loss due to increased operating expenses related to investments in growth initiatives.
Revenue increased to $33.2 million, up 44% year-over-year.
Instrument revenue was $17.4 million, a 74% increase year-over-year.
Consumables revenue was $13.8 million, a 24% increase year-over-year.
Net loss for the quarter was $88.0 million, compared to a net loss of $60.0 million for the same period last year.
Revenue by Segment
Forward Guidance
PacBio anticipates revenue for the full year 2022 will be between $125 million and $135 million.
Positive Outlook
- Continued growth in instrument sales.
- Increased adoption of PacBio technology in key markets.
- Expansion of the installed base of Sequel II/IIe instruments.
- Growing demand for PacBio consumables.
- Strategic partnerships to drive further innovation and market reach.
Challenges Ahead
- Global supply chain disruptions.
- Potential impact of economic downturn on customer spending.
- Increased competition in the long-read sequencing market.
- Uncertainties related to the COVID-19 pandemic.
- Fluctuations in foreign exchange rates.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...